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ARTICLE
Conformational pathway provides unique
sensitivity to a synaptic mGluR
Chris H. Habrian1, Joshua Levitz2,3, Vojtech Vyklicky 2, Zhu Fu2, Adam Hoagland2,
Isabelle McCort-Tranchepain4, Francine Acher 4 & Ehud Y. Isacoff1,2,5,6*
Metabotropic glutamate receptors (mGluRs) are dimeric G-protein–coupled receptors that
operate at synapses. Macroscopic and single molecule FRET to monitor structural rearran-
gements in the ligand binding domain (LBD) of the mGluR7/7 homodimer revealed it to have
an apparent afﬁnity ~4000-fold lower than other mGluRs and a maximal activation of only
~10%, seemingly too low for activation at synapses. However, mGluR7 heterodimerizes, and
we ﬁnd it to associate with mGluR2 in the hippocampus. Strikingly, the mGluR2/7 hetero-
dimer has high afﬁnity and efﬁcacy. mGluR2/7 shows cooperativity in which an unliganded
subunit greatly enhances activation by agonist bound to its heteromeric partner, and a unique
conformational pathway to activation, in which mGluR2/7 partially activates in the Apo state,
even when its LBDs are held open by antagonist. High sensitivity and an unusually broad
dynamic range should enable mGluR2/7 to respond to both glutamate transients from nearby
release and spillover from distant synapses.
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G-protein–coupled receptors (GPCRs), the largest class ofmembrane signaling proteins, respond to a wide array ofextracellular stimuli to initiate intracellular signaling via G
proteins and arrestins1. Recent studies have provided snapshots
of GPCR structures in distinct conformations2–5 and revealed
that they are extremely dynamic6–13. The conformational
dynamics appear to be central to ligand recognition, activation
and signaling by GCPRs9,14,15.
Membrane receptors have evolved to respond to precise spatio-
temporal concentration proﬁles of extracellular ligands. In the
nervous system, neurotransmitter receptors encounter a wide
range of neurotransmitter concentrations and spatio-temporal
proﬁles. Key factors contributing to these dynamics are the small
extracellular volume of the synaptic cleft, pumps and/or enzymes
that remove neurotransmitter and diffusion. Additionally, neu-
rotransmitter receptors can be localized within the synapse both
pre- and postsynaptically as well as extrasynaptically where they
can encounter different sources of neurotransmitter released
either locally, which brieﬂy reaches low millimolar levels within a
synaptic cleft, and spillover from nearby synapses, which reaches
lower concentrations16. Thus, receptor activation by transmitter
needs to be tuned to suit its localization and sensitivity to
transmitter. GPCRs have evolved to respond to diverse signal
types at various cellular locations and produce a large variety of
responses. Structural and functional diversity in receptor families
can provide unique responses in ligand activation and localiza-
tion, as can specialized post-translational modiﬁcation or inter-
action with regulatory proteins3,17,18.
Most synaptic receptors have apparent afﬁnities (EC50s) in the
low micromolar range, or lower19–21. One intriguing outlier is
metabotropic glutamate receptor 7 (mGluR7). This receptor, one of
an 8-member family of class C GPCRs22, has been reported, based
on effector activation, to have an apparent afﬁnity that is much
lower than that of the other mGluRs23. These properties have led to
the idea that mGluR7 may only function at locations very near the
site of glutamate release24, and best at synapses with high repetitive
activity and enclosed extracellular volumes25. Even under these
conditions, it is not clear how effectively mGluR7 is activated.
mGluRs are veriﬁed targets of numerous neurological disorders
and are considered to contain great potential as therapeutic tar-
gets26–28, unfortunately many years of work have resulted in no
mGluR targeting drugs approved for medical use at the present
time. Recent work has, for the ﬁrst time, revealed structures of the
active and inactive conformations allowing for more detailed
understanding and interpretation of the molecular mechanism of
mGluR activation29. mGluRs are strict dimers30,31 and dimer-
ization is required for efﬁcient G protein activation32. Hetero-
dimerization can occur between group I members mGluR1 and 5
and within and between members of group II (mGluR2 and 3)
and group III (mGluR4, 6, 7, and 8)30,31. Functional analysis of
one such potential combination, mGluR2/mGluR3 (mGluR2/3),
showed that heterodimerization can impart unique functional
properties resulting in distinct basal activity31. We wondered if
heterodimerization of mGluR7 would increase its activation by
glutamate. While, overlapping expression suggests that mGluR7
may be co-expressed with other mGluRs and therefore might
heterodimerize in the brain, only one example of heterodimer
formation has been demonstrated to date in neurons, that of
mGluR2/433,34. But the mGluR2/4 heterodimer resembles its
parents functionally, not surprisingly since they themselves have
similar activation in response to glutamate34.
To analyze the activation of the mGluR7/7 homodimer, we
ﬂuorescently labeled with donor and acceptor Foster resonance
energy transfer (FRET) dyes a protein tag fused to the mGluR7
N-terminal, immediately before the ligand binding domain
(LBD). We measured FRET changes between the LBDs of the
dimer, which result from the conformational rearrangements of
activation, in which the receptor dimer transitions from a state
with both LBDs empty and open and the receptor at rest (Roo) to
a state in which both LBDs are occupied by agonist and closed
and the receptor is activated (Acc)11,13,30,31,35. Measurements in
live HEK 293T cells and at the single-molecule level on immune-
puriﬁed dimers13,31 conﬁrm very low afﬁnity23 and efﬁcacy36. We
conﬁrm and extend these ﬁndings measuring an apparent afﬁnity
of 38 mM and a max efﬁcacy of 10%, values too low, it would
appear, to support activation by the concentrations estimated for
synaptic glutamate37,38. However, we ﬁnd that mGluR7 associates
with mGluR2 in hippocampus and that the mGluR2/7 hetero-
dimer has even higher afﬁnity and efﬁcacy than mGluR2/2, a
wider dynamic range, showing that heterodimerization can alter
the glutamate response of an mGluR. The boosted properties are
associated with a special heteromeric cooperativity that boosts the
afﬁnity and efﬁcacy of each subunit in the dimer, and which
primes the receptor for activation even in absence of agonist
through a unique tendency of the LBDs to enter the rotated
activated conformation even when they are in the open, Apo
state. Combined with unusually fast kinetics, these properties
appear to make mGluR2/7 uniquely suited to activate in response
to synaptic glutamate.
Results
mGluR7 activates with very low afﬁnity and efﬁcacy. To
understand the unusually low apparent glutamate afﬁnity of
mGluR7/7 observed earlier23, we compared the ligand-induced
conformational rearrangement of mGluR7/7 with that of mGluR2/2.
As previously described13,30, N-terminally SNAP-tagged mGluR2
expressed in HEK293T cells and labeled with Alexa-647 (acceptor)
and DY-547 (donor) ﬂuorophores (Förster radius 52 Å) showed a
robust glutamate-induced FRET decrease, which increased with
glutamate concentration between 1 µM and 1mM (Fig. 1a), with an
EC50 of 18.7+ 0.6 µM (Supplementary Fig. 1a). A similarly
N-terminally SNAP-tagged mGluR7, expressed at comparable levels,
as assessed from SNAP dye staining, showed no detectable FRET
change at up to 1mM glutamate, and a barely measurable FRET
decrease at 10mM glutamate (Fig. 1b), which was >30-fold smaller
than that observed at 1mM glutamate in mGluR2 (Fig. 1c). To test
whether interaction with a signaling complex affected activation,
Gβγ-activated GIRK1 inward rectiﬁer potassium channel was co-
expressed with the receptor. We observed no change in the
glutamate-induced FRET response of either SNAP-mGluR2
(Supplementary Fig. 1a) or SNAP-mGluR7 in the presence of
GIRK channels (Supplementary Fig. 1b). Nor did a switch to another
donor/acceptor dye pair, which gave robust glutamate-induced FRET
responses in SNAP-mGluR2 make for detectable responses in SNAP-
mGluR7 (Supplementary Fig. 1c). In contrast to SNAP-mGluR7, a
SNAP-tagged version of another group III mGluR, mGluR4, which
has been shown to have low micromolar apparent glutamate afﬁnity,
showed glutamate-induced FRET decreases that were similar in
amplitude and concentration dependence to those of mGluR2
(Supplementary Fig. 1d), and similar to those reported earlier for
several of the other mGluRs13,30.
In HEK293T cells it was not possible to go to glutamate
concentrations above 10 mM. We therefore turned to isolated
receptors. Receptors expressed in HEK293T cells were labeled
with a mixture of SNAP-reactive donor and acceptor ﬂuoro-
phores, detergent solubilized, immune-puriﬁed and tethered by
biotinylated secondary antibodies at low density to coverslips that
were passivated with a lawn of polyethylene glycol13. We used
single-molecule FRET (smFRET) in order to measure the
absolute FRET levels and dynamic changes associated with
ligand-induced conformational changes in the LBDs. We imaged
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the donor and acceptor dyes using total internal reﬂection
ﬂuorescence (TIRF) microscopy13,31 (Supplementary Fig. 1e).
Our baseline for comparison was mGluR2. As previously
observed13, in zero glutamate, the two unliganded LBDs of
mGluR2 are both open and in the resting conﬁguration (Roo) and
the inter-subunit distance between donor and acceptor SNAP
dyes is relatively small, giving a high FRET level of ~0.45, which
can be seen in single-molecule trajectories from an individual
dimer (Fig. 1d, left top) and in histograms that compile
measurements from many dimers (Fig. 1e, solid gray line). At
1 mM glutamate, the LBDs of mGluR2 are maximally bound,
closed and rotated into the activated conformation (Acc) to yield
a low FRET level of ~0.2 (Fig. 1d, left bottom; Fig. 1e, dashed gray
line). At an intermediate glutamate concentration of 10 µM, near
the EC50 of the ensemble concentration-response FRET mea-
sured both in live HEK293T cells (Supplementary Fig. 1a) and on
isolated protein in smFRET (Fig. 1f, red symbols), mGluR2
transitions between the high and low FRET states (Fig. 1d, left
middle), yielding high conformational dynamics, as measured by
donor-acceptor cross-correlation (Supplementary Fig. 1f, left).
Similar to mGluR2, mGluR7 in zero glutamate had a stable
FRET level of ~0.45 (Fig. 1d, right top; Fig. 1e, black symbols).
Remarkably, at 10 mM glutamate (10-fold higher than the
saturating concentration tested in mGluR2), only rare transitions
were seen in mGluR7 from the high FRET state to a low FRET
state of ~0.2 (Fig. 1d, right middle). While the low FRET level was
similar to that of mGluR2, in mGluR7 these events were so short-
lived and infrequent that a low FRET peak was barely observable
in the pooled histogram (Fig. 1e, red symbols). The low FRET
peak increased with increasing concentration, reaching a
maximum between 100 and 250 mM (Fig. 1d, right bottom;
Fig. 1e, blue and cyan symbols; Fig. 1f; Supplementary Fig. 1g,h).
The EC50 of the mGluR7 low FRET peak concentration-response
was 38.3 mM, an apparent glutamate afﬁnity that is ~4,000-fold
lower than that of mGluR2 (Fig. 1f). Single-molecule trajectories
showed that, although at saturating glutamate (≥100mM)
transitions to the low FRET state occurred more frequently than
at 10 mM glutamate, the maximal occupancy of the glutamate
activated state only reached ~10% (Fig. 1f). The low degree of
maximal activation indicates that glutamate is a low efﬁcacy
partial agonist of mGluR7.
Increasing mGluR7 efﬁcacy. To pursue the surprising observa-
tion that glutamate is such a low efﬁcacy agonist of mGluR7, we
asked whether a point mutation in the LBD agonist binding
pocket, N74K, which has been shown to increase apparent afﬁnity
of mGluR6 and mGluR736, would also affect efﬁcacy. Measure-
ments in smFRET showed that 10 mM glutamate induces more
frequent activation transitions in mGluR7(N74K) (Fig. 2a, top)
and greater occupancy of the activated low FRET (~0.2) state
(Fig. 2a, bottom) than seen in wild-type mGluR7 at >10X higher
glutamate (Fig. 1e). This reﬂects an increase in the stabilization of
glutamate binding within the LBD.
We next asked if it was possible to increase agonist binding and
occupancy at the binding site of wild-type mGluR7 using a
synthetic agonist. We turned to a new synthetic group III selective
agonist, LSP4-2022, which is highly selective for mGluR4,
activating it efﬁciently at nanomolar concentration39,40. We
found that LSP4-2022 is a potent activator of mGluR7 at higher
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Fig. 1 Glutamate activates mGluR7/7 with low afﬁnity and low efﬁcacy. a, b Homodimers of SNAP-tagged mGluR2/2 (a) and mGluR7/7 (b). Left)
Schematics (top) and images of expressing HEK293 cells labeled with a mixture of donor (green) and acceptor (red) dyes. Right) Live-cell FRET traces
show responses to ascending concentrations of glutamate. Scale bars are 5 µm. c Mean+ S.E.M. fractional change in FRET of SNAP-mGluR2/SNAP-
mGluR2 (1 mM glutamate, n= 3) and SNAP-mGluR7/SNAP-mGluR7 (10mM glutamate, n= 3, *p < 0.05). Individual data points (black dots) and s.e.m.
(error bars). d Representative smFRET traces of SNAP-mGluR2/SNAP-mGluR2 (left) and SNAP-mGluR7/SNAP-mGluR7 (right) at different glutamate
concentrations. e Histogram of smFRET distributions of SNAP-mGluR7/SNAP-mGluR7 in 0 (5 movies, 288 molecules), 10mM (6 movies, 215 molecules),
100mM (5 movies, 261 molecules) and 250mM (5 movies, 253 molecules) glutamate concentrations (colored symbols and interpolation lines, error bars
are s.e.m.) and of SNAP-mGluR2/2 in 0 (5 movies, 230 molecules) and 1 mM (4 movies, 197 molecules) glutamate (solid and broken gray lines,
respectively). f Titration curve of low smFRET (activated state) peak in histograms of SNAP-mGluR2/SNAP-mGluR2 (red circle) and SNAP-mGluR7/
SNAP-mGluR7 (black triangle; normalized as black dashed line). Donor (BG-DY-547) and acceptor (BG-Alexa 647) dyes imaged at 10 Hz for ensemble
FRET in cells (a–c) and 10 Hz for smFRET on the isolated protein (d–f).
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concentrations. At 20 μM LSP4-2022, smFRET traces showed
frequent transitions to the low FRET activated conformation, and
occupancy of the low FRET conformation reached ~65% at 3 mM
LSP4-2022 (Fig. 2b and Supplementary Fig. 2a), the highest
concentration we could test, indicating an at least 6-fold greater
efﬁcacy than that of glutamate (compare Figs. 1e and 2b).
We next asked whether glutamate itself could be turned into a
more potent agonist of mGluR7 if the glutamate were lodged
stably into the LBD binding pocket. To achieve this, we used a
photoswitchable tethered glutamate, maleimide-azobenzene-
glutamate D-MAG-0 (Supplementary Fig. 2b), which attaches
covalently to the LBD and docks its glutamate into the agonist
binding pocket in mGluRs in one of the photo-isomeric
conﬁgurations of azobenzene, achieving a high effective
concentration31,41,42. When conjugated to an engineered cysteine
on the lower lobe of the mGluR7 LBD (K319C), D-MAG-0
activated mGluR7 in the trans conﬁguration of azobenzene (in
the dark and under ~500 nm light), and deactivated in the cis
conﬁguration (~380 nm light), as measured by activation of the G
protein activated inward rectiﬁer potassium channel, GIRK1
(F137S) (Supplementary Fig. 2c, d). The K319C mutation did not
alter the apparent afﬁnity of mGluR7 for glutamate (Supplemen-
tary Fig. 2e). Thus, D-MAG-0 is an agonist of mGluR7 in the
trans conﬁguration of azobenzene. This enabled us to perform
FRET experiments to monitor the activation rearrangement of
the LBD and photoswitch D-MAG-0. We used illumination at
532 nm to simultaneously excite the FRET donor and photo-
isomerize D-MAG-0 into the agonistic trans state.
smFRET was performed on puriﬁed SNAP-mGluR7(K319C)
homodimers that were labeled with donor and acceptor dyes on
the SNAP and D-MAG-0 on K319C in the D-MAG-0 activated
state. The smFRET trajectories showed frequent transitions into
the low FRET activated state (Fig. 2c, top). Histograms that
pooled the behavior of many dimers showed that the occupancy
of the activated low FRET state was ~50% (Fig. 2c, bottom).
Addition of the high afﬁnity orthosteric antagonist LY341495
caused a nearly complete disappearance of the low FRET
peak (Fig. 2c, bottom), consistent with displacement of the
glutamate of D-MAG-0 from the orthosteric binding site. These
observations show that the tethered glutamate of D-MAG-0
stabilizes the activated conformation of mGluR7 approximately
5-fold more effectively than does saturating free glutamate. This
suggests that the low efﬁcacy of glutamate in mGluR7 may result
from a mismatch between the kinetics of glutamate binding and
unbinding and the kinetics of LBD closure/activation rotation,
which are overcome when trans D-MAG-0 jams its glutamate
into the ligand binding pocket.
mGluR7 heterodimerization with mGluR2. Our observations, so
far, suggest that mGluR7 has an active state conformation that is
similar to that of other mGluRs, that this conformation is only
weakly stabilized by glutamate, and that pointing glutamate into the
binding pocket on a stiff tether boosts efﬁcacy, indicating that
mGluR7 is capable of strong activation by glutamate. We wondered
whether some modiﬁcation of mGluR7 could change its properties
so that it would be more strongly activated by glutamate.
It is known that mGluR7 can heterodimerize with other
mGluRs30 and earlier work suggests that mGluR7 expression may
overlap with that of other mGluRs in the mammalian brain43. We
wondered, therefore, if mGluR7 heterodimerization occurs in
neurons and, if so, whether a heterodimer containing mGluR7
would have stronger activation by physiological levels of
glutamate. mGluR7 is expressed strongly in the hippocampus,
olfactory bulb and tubercule, and cortex44. In the hippocampus,
other mGluRs are also expressed, including group I members
mGluR1 and 5 and group II members mGluR2 and 3, with the
highest expression of mGluR5 and 245. Earlier studies showed
that mGluRs co-assemble within and between groups II and III
members, but that these do not assemble with group I members,
which only heterodimerize within group I30,31. This led us to
consider possible assembly of mGluR2 with mGluR7. We found
that mGluR2 expression overlaps with that of mGluR7 (Supple-
mentary Fig. 3a–c). We used anti-mGluR7 antibody to immune-
precipitate mGluR7 from adult rat hippocampi and found that
mGluR2 co-precipitates with mGluR7 (Supplementary Fig. 3d).
To further test the potential for mGluR7 heterodimerization in
native tissue, we asked whether mGluR3 and mGluR7 interact in
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Fig. 2 Increasing mGluR7 efﬁcacy. a–c Representative smFRET traces (top) and smFRET histograms (bottom) of homodimers of SNAP-mGluR7(N74K) (0
Glu: 4 movies, 124 moleucles, 10 mM Glu: 4 movies, 140 molecules, s.e.m. error bars) compared to SNAP-mGluR2 in glutamate (a); SNAP-mGluR7 in
LSP4-2022 (0: 4 movies, 145 molecules, 1 μM: 5 movies, 197 molecules, 20 μM: 5 movies, 128 molecules, 1 mM: 5 movies, 122 molecules, 3 mM LSP4: 6
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rat cortex. We ﬁnd that we mGluR3 co-precipitates with mGluR7
(Supplementary Fig. 3d). These results suggest that mGluR7
either heterodimerizes with mGluR2 in the hippocampus and
with mGluR3 in the cortex, or potentially associates with these
proteins indirectly.
mGluR2/7 has high glutamate afﬁnity. Having found that
mGluR7 associates with mGluR2, we examined the functional
properties of the mGluR2/7 heterodimer. We co-expressed
SNAP-mGluR7 and CLIP-mGluR2 in HEK 293 cells and
labeled SNAP-mGluR7 with the SNAP-selective acceptor dye BG-
Alexa 647 and CLIP-mGluR2 with the CLIP-selective donor dye
BC-DY-547 (Fig. 3a). Dye labeling was speciﬁc for SNAP or CLIP
and labeling of SNAP-mGluR7 and CLIP-mGluR2 was compar-
able (Supplementary Fig. 3f, g), indicating that they expressed at
comparable levels. The co-expression of SNAP-mGluR7 and
CLIP-mGluR2 is expected to yield three dimer stoichiometries:
the homodimeric SNAP-mGluR7/SNAP-mGluR7; the homo-
dimeric CLIP-mGluR2/CLIP-mGluR2, and the heterodimeric
SNAP-mGluR7/CLIP-mGluR2. Of these, only the heterodimer
combines the donor and acceptor and produces a FRET signal34.
Live-cell ensemble FRET experiments on SNAP-mGluR7/CLIP-
mGluR2 revealed large glutamate-induced concentration-depen-
dent decreases in FRET for mGluR2/7 (Fig. 3b). The behavior of
mGluR2/7 differed greatly from that of the mGluR7/7. mGluR2/7
had responses to low micromolar glutamate, whereas mGluR7/7
required 10mM glutamate to give a measurable response
(compare Fig. 3b to Fig. 1b). The reverse protein tagging—
CLIP-mGluR7/SNAP-mGluR2—showed a similar high apparent
afﬁnity for glutamate (Supplementary Fig. 3h). The glutamate
concentration-response relation of mGluR2/7 was biphasic,
consisting of a major component (~80% of total ΔFRET) with
high afﬁnity (EC50high= 2.7 μM SEM: 3.8 µM), which is 7 fold
lower than mGluR2/2, and a minor component (~20% of total
ΔFRET) with lower afﬁnity (EC50low= 2.5mM SEM: 0.58 mM)
(Fig. 3c).
Live cell assays face challenges at both low and high glutamate
concentrations. Unhealthy cells may release glutamate and
interfere with detection of responses to low micromolar glutamate,
and it is not possible to go above 10mM glutamate. We therefore
turned to single-molecule analysis on the puriﬁed protein, where
glutamate concentration could be accurately deﬁned throughout
the concentration range and where we measure absolute FRET.
Individual smFRET trajectories showed that in zero glutamate
mGluR2/7 heterodimers spend most of the time at a FRET level of
~0.4, whereas at 10mM glutamate they were mainly at a low
FRET level of ~0.2, and at 10 µM glutamate they transitioned back
and forth between these levels (Fig. 4a). Occupancy histograms
that pooled many mGluR2/7 dimers showed ~50% occupancy of
the low FRET active state at 10 µM glutamate (Fig. 4b, c). At 10
mM glutamate, mGluR2/7 mostly occupied the low FRET
activated state, but there remained a small high FRET shoulder,
which disappeared at 100mM glutamate (Fig. 4b). The low
smFRET (activated state) concentration-response relation for
mGluR2/7 was biphasic, consisting of a major (~80%) high afﬁnity
component (EC50high= 8.4 μM) and a minor (~20%) low afﬁnity
component (EC50low= 9.9mM) (Fig. 4c).
We wondered if the glutamate response of mGluR3/7 hetero-
dimers would also differ from that of the respective homodimers.
Samples were prepared in the same manner as for mGluR2/7
heterodimers and imaged in smFRET. We found that, in absence of
glutamate, mGluR3/7 occupies the active state ~70% of the time
(Supplementary Fig. 4a), signiﬁcantly higher than what we
previously observed in the mGluR3/3 homodimer13. In 10 μM
glutamate the active state occupancy was ~95% (Supplementary
Fig. 4a).
We wondered whether the distinct components of the FRET
concentration-response in mGluR2/7 reﬂect the closure at the
different LBDs, i.e., if the high afﬁnity mGluR2 LBD closes in sub-
100 µM range and the low afﬁnity mGluR7 LDB closes in the
above-100 µM range. To examine this, we tested the behavior of a
heterodimer that co-assembles a wild-type mGluR2 with a
binding site mutant version of mGluR2, mGluR2 (Y216A and
D295A; known as the YADA mutant). This YADA mutant was
developed by J.P. Pin’s group in mGluR5, where, as a homodimer,
it was shown to not be activated by 10 mM glutamate and was
shown to have a biphasic effector activation concentration-
response as a heterodimer with a wild-type subunit of mGluR5
[mGluR5/mGluR5(YADA)]46. The biphasic concentration-
response was attributed to binding glutamate at low concentra-
tion by the wild-type LBD and at higher concentration by the
YADA LBD, and closure of a single LBD was interpreted to be
sufﬁcient for only partial activation. We co-expressed CLIP-
mGluR2 and SNAP-mGluR2(YADA) and labeled with the
SNAP-selective acceptor dye BG-Alexa-647 and the CLIP-
selective donor dye BC-DY-547. The mGluR2/mGluR2(YADA)
dimer had a biphasic FRET concentration-response relation
(Fig. 4c), conﬁrming earlier observations13, and supporting the
notion that the biphasic concentration-response relation of
mGluR2/7 does indeed represent the closure over different
concentration ranges of the high afﬁnity mGluR2 LBD and the
c
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low afﬁnity mGluR7 LBD. The high afﬁnity component of
mGluR2/mGluR2(YADA) produced only a small fraction (~10%)
of maximal activation, and this stood in stark contrast to what we
observed in mGluR2/7 where the ﬁrst component was 10-fold
larger (Fig. 4c). These ﬁndings indicate that closure of a single
wild-type mGluR2 subunit is much more efﬁcient in activating
the receptor when partnered in the dimer with an mGluR7 than
with another mGluR2.
Enhanced efﬁcacy of one-subunit liganding in mGluR2/7. The
above results suggest that the heterodimeric interaction between
mGluR2 and mGluR7 more strongly favors the activated state
than do homodimeric interactions. We explored this further by
examining trans-activation, whereby binding of ligand to one
subunit activates G-protein interaction in the partner
subunit46,47. To speciﬁcally activate only the mGluR2 subunit of
the mGluR2/7 heterodimer, we selectively attached a photo-
switched tethered ligand to mGluR2. We used the photoswitch-
able tethered glutamate, benzylguanine azobenzene glutamate
(BGAG12), which attaches covalently to the N-terminal SNAP tag
of SNAP-mGluR2, where we conjugate ﬂuorophore for our FRET
analysis. As shown earlier48, this BGAG12-labeled SNAP-mGluR2
is photo-activated by illumination at 380 nm. The tether of
BGAG12 is short, so it only ligands and activates the subunit to
which it is attached31. To cripple G protein signaling of the
photoswitch-controlled SNAP-mGluR2 subunit, we introduced
the mutation F756D, which prevents G-protein coupling49.
SNAP-mGluR2(F756D) was co-expressed with wild-type
mGluR7 along with the GIRK1 channel. The co-expression was
expected to yield three mGluR dimer stoichiometries: the
homodimeric SNAP-mGluR2(F756D)/SNAP-mGluR2(F756D),
where both subunits would be conjugated to BGAG12 but neither
could couple to G protein; the homodimeric mGluR7/mGluR7,
which would be non-responsive to light because of lack of an
attached BGAG12; and the heterodimeric SNAP-mGluR2
(F756D)/mGluR7, the only dimer potentially capable of signaling
if BGAG12 activation of the signaling-dead mGluR2 were able to
trans-activate mGluR7 (Supplementary Fig. 4b).
Activation of BGAG12 on the SNAP-mGluR2(F756D) subunit
by illumination at 380 nm induced an inward GIRK1 current that
was reversed by illumination at 500 nm, the wavelength that
causes unbinding (Supplementary Fig. 4c, d). As expected, cells
expressing only the G-protein-coupling-dead SNAP-mGluR2
(F756D) had no photocurrent (Supplementary Fig. 4d). These
results demonstrate that the mGluR2/7 heterodimer possesses
trans-activation. This result was conﬁrmed by activation of
GIRK1 channels with free glutamate over a concentration range
corresponding to the high afﬁnity activation rearrangement phase
in mGluR2/7 (Supplementary Fig. 4e). As seen in the smFRET
measure of the conformational change associated with activation,
the foot of the curve was shifted to the left compared to that of the
mGluR2/2 homodimer. The amplitude of the photocurrent was
19.7+ 1.5 % (n= 42 cells) that of the current induced by 1 mM
glutamate (Supplementary Fig. 4b).
We wondered if the enhanced efﬁcacy in mGluR2/7 could be
detected using a free agonist that could only activate mGluR2 and
antagonize mGluR7. The concentration-response relation for
effector trans-activation by the group II agonist DCG-IV
measured in patch clamp recordings in cells co-expressing the
GIRK1 channel showed similar concentration-response relations
for mGluR7/SNAP-mGluR2(F756D) and SNAP-mGluR2/SNAP-
mGluR2, but, once again, at the foot of the concentration-
response relation, the mGluR2/7 heterodimer was more sensitive
than the mGluR2/2 homodimer (Supplementary Fig. 4f), even
though mGluR2/2 possesses two subunits that bind DCG-IV and
two subunits capable of G-protein activation, whereas the
heterodimer has only one. The observation of higher apparent
afﬁnity of mGluR2/7 in effector activation by DCG-IV led us to
ask whether we could detect a greater potency of DCG-IV in
inducing transition to the activated conformation in mGluR2/7.
In smFRET, 100 μM DCG-IV induced near-complete (~90%)
occupancy of the activated conformation (Fig. 5b), conﬁrming
that mGluR2/7 can be strongly activated by liganding only the
mGluR2 LBD and antagonizing mGluR750. At 10 nM DCG-IV,
mGluR2/2 had low (~5%) occupancy of the activated conforma-
tion, but mGluR2/7 had about 5-fold greater (~25%) activated
conformation occupancy (Fig. 5b). Together, these observations
of activation rearrangement in the receptor and activation of the
effector show that liganding of an mGluR2 LBD activates the
receptor more potently when mGluR7 is the partner subunit than
when the partner is another mGluR2 subunit.
Having seen that liganding of just the mGluR2 subunit can
strongly activate mGluR2/7, we examined the effect of agonist
binding to only the mGluR7 subunit. We isolated receptor protein
from cells co-expressing SNAP-mGluR7 and CLIP-mGluR2,
a
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where the group III selective agonist LSP4-2022 could be used to
bind only to the mGluR7 subunit of mGluR2/7 (Fig. 5c). We
observed two striking differences between LSP4-2022 activation of
the mGluR7/7 homodimer and the mGluR2/7 heterodimer. A ﬁrst
difference was that, whereas 1 mM LSP4-2022 produced slightly
more than 50% occupancy of the activated conformation in
mGluR7/7, activation was almost complete in mGluR2/7 (Fig. 5d).
Indeed, even 1 µM LSP4-2022 was sufﬁcient to shift the smFRET
distribution slightly more than half-way toward the activated low
FRET state (Fig. 5d). This gives the mGluR7 subunit an
approximately 1000-fold higher apparent afﬁnity for LSP4-2022
when partnered with mGluR2 than when partnered with another
mGluR7. A second difference was that in mGluR2/7 LSP4-2022
concentrations near the EC50 produced a single broad distribution
with a peak, which was intermediate between the high FRET
resting and low FRET activated states, as opposed to two resolved
distributions of the high FRET resting and low FRET activated
states, as seen in mGluR7/7 (Fig. 5d). This single broad smFRET
distribution is similar to what we have seen with glutamate
activation of the mGluR2/7 heterodimer, above (Fig. 4b). We
examine this further below.
Having seen that synthetic agonists that are selective for either
the mGluR2 subunit or the mGluR7 subunit produce stronger
activation in mGluR2/7 than in either mGluR2/2 or mGluR7/7,
we wanted to determine if the native agonist glutamate is also a
stronger activator in mGluR2/7. To conﬁne the glutamate to one
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of the subunits, we once again tethered the photoswitchable
tethered glutamate, D-MAG-0, to the mGluR7 LBD (Fig. 5e).
smFRET analysis showed that mGluR2/7 with a tethered ligand
only on the one mGluR7 subunit spends ~90% of the time in the
activated low-FRET state of ~0.2, higher than the ~50% activation
seen in the mGluR7/7 homodimer in which both subunits had the
tethered agonist (Fig. 5f). In addition, we found that, whereas 100
µM of the competitive antagonist LY341495 almost completely
blocked activation of mGluR7/7 by trans D-MAG-0 (Fig. 2c), it
had little effect on activation by trans D-MAG-0 of mGluR2/7
(Fig. 5f). The results suggest that D-MAG-0 binds with higher
afﬁnity to the mGluR7 LBD when it is partnered with mGluR2
than when it is partnered with another mGluR7.
Together these experiments show that mGluR7 enhances
activation by mGluR2 and mGluR2 enhances activation by
mGluR7, so that the heterodimer has greater sensitivity to
glutamate and synthetic agonists and stronger activation by single
subunit agonism than seen in either the mGluR2/2 homodimer, or
the mGluR7/7 homodimer.
Spontaneous rearrangements and altered kinetics in mGluR2/7.
One striking property of the mGluR2/7 heterodimer is the shape
of the smFRET histogram at intermediate concentrations.
mGluR7/7 had two well-resolved smFRET distributions—the
resting high-FRET state and the activated low-FRET state (Figs. 1e
and 2)—and the occupancy of the former decreases as occupancy
of the latter increases with a progressive rise in agonist con-
centration, as also observed earlier in the mGluR2/2 and mGluR3/
3 homodimers and the mGluR2/3 heterodimer13,31. In contrast,
the mGluR2/7 heterodimer smFRET histogram is a single, broa-
dened distribution, which shifts progressively to lower FRET levels
as agonist concentration increased, whether the agonist was glu-
tamate, which could bind to both the mGluR2 and mBGluR7
LBDs (Fig. 4b), or the group III-selective ligand LSP4-2022, which
binds to only the mGluR7 LBD (Fig. 5d).
We examined this further and found that at zero glutamate the
smFRET distribution of mGluR2/7 was also broadened and left-
shifted with respect to both mGluR2/2 and mGluR7/7 at zero
glutamate (Fig. 6a). One possible explanation for such behavior is
spontaneous closure of LBDs leading to basal activation. To test
this, we applied 100 µM of the group II and group III competitive
antagonist LY341495. LY341495 binds in the orthosteric site,
holds the LBD in the open conformation30 and blocks the
activation rearrangement that is induced by glutamate bound in
the orthosteric site of mGluR2/2 and mGluR3/3, as well as by
calcium ion binding at an allosteric site in mGluR3/313 (PDB
b
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Fig. 6 Spontaneous conformational rearrangements of mGluR2/7 in the Apo state. a, b 0 glutamate smFRET histograms of SNAP-mGluR2/SNAP-mGluR2,
SNAP-mGluR7/SNAP-mGluR7 and CLIP-mGluR2/SNAP-mGluR7 show a shift to lower FRET values in mGluR2/7 (a), associated with spontaneous
transitions to an intermediate FRET state of ~0.3. c, d The left shift of the 0 glutamate CLIP-mGluR2/SNAP-mGluR7 (5 movies, 191 molecules, s.e.m. error
bars) smFRET histogram relative to that of SNAP-mGluR2/SNAP-mGluR2 (6 movies, 257 molecules, s.e.m. error bars) (c) and the spontaneous transitions
to the intermediate FRET state (d) are not altered by 100 µM of the orthosteric antagonist LY341495 in 0 glutamate (5 movies, 230 molecules, s.e.m. error
bars). e, f The left shift of the 0 glutamate CLIP-mGluR2/SNAP-mGluR7 smFRET histogram (e) and the spontaneous transitions to the intermediate FRET
state (f) are blocked by combined negative allosteric modulators for mGluR2 (either 11 µM Ro-5229 (6 movies, 160 molecules, s.e.m. error bars) or 1.2 µM
MNI-137 (6 movies, 154 molecules, s.e.m. error bars)) and mGluR7 (125 µM ADX 71743) in 0 glutamate. a–f BC-DY-547 or BG-DY-547 (donor) and BG-
Alexa-647 (acceptor) imaged at 10 Hz. g, h Whole cell patch clamp recording (Vh=−60 mV; [K+]in= [K+]out= 150mM) in HEK293T cells co-
expressing mGluR2, mGluR7 and the GIRK1(F137S) channel have basal inward current, which is reversibly inhibited by the GIRK pore blocker Ba2+, but not
affected by the combined negative allosteric modulators for mGluR2 (1 µMMNI-137) and mGluR7 (3 µM ADX 71743) (g), even though these are sufﬁcient
to completely block activation by 1 mM glutamate (h).
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3MQ4). However, LY341495 did not alter the smFRET distribu-
tion of the mGluR2/7 heterodimer (Fig. 6c), indicating that the
broadening and shift to the left in mGluR2/7 is not due to
spontaneous LBD closure in the Apo state.
mGluRs respond to agonist in a sequence of steps: agonist
binding favors closure of the LBDs, the closed LBDs rotate, and
this triggers a rotation of the transmembrane domain (TMD) that
opens the intracellular-facing G protein docking site29,51. We
tested negative allosteric modulators (NAMs) of mGluR7 (ADX-
71743) and mGluR2 (Ro 64-5229 and MNI-137), which bind in
the TMD and stabilize the resting state52–55 and, so, would be
expected to stabilize the open and non-rotated (resting)
conformation of the LBD. A combination of either of the
mGluR2 NAMs with the mGluR7 NAM narrowed the smFRET
distribution and shifted it to the right (Fig. 6e), as would be
expected for a negative allosteric effect that pushes a partially
activated receptor into the resting state.
To understand the molecular motions underlying the shift in
smFRET distribution, we analyzed single molecule trajectories in
zero glutamate. We observed spontaneous transitions from a high
FRET resting state of ~0.45 to an intermediate FRET state of ~0.3
(Fig. 6b and Supplementary Fig. 5, top). These spontaneous
transitions persisted in the presence of LY341495 (Fig. 6d and
Supplementary Fig. 5, second from top), but were eliminated by
the NAMs, which stabilized the receptors in the high FRET state
(Fig. 6f, and Supplementary Fig. 5, bottom two). These ﬁndings
suggest that, in the Apo state, mGluR2/7 spontaneously transi-
tions into a conformational intermediate on the activation
pathway in which the LBDs are open but rotated.
We next asked whether the Apo state intermediate of mGluR2/
7 represents the G protein signaling state of the receptor. To this
test this we co-expressed mGluR2 and mGluR7 in HEK293T cells
along with the GIRK channel and measured GIRK current.
Application of 1 mM barium, to block the GIRK channels, elicited
a reduction in standing inward current, which could be due to
either or both basal activity of the receptor and excess free Gβγ
(Fig. 6g). 1 mM glutamate elicited a large inward current above
this basal level and this was completely blocked (96.7 ± 2.1%, n=
4) by a combination of 3 μM ADX71743 (the mGluR7 NAM) and
1 μM MNI-137 (the mGluR2 NAM) (Fig. 6g, h). However, the
combined NAMs on their own had no effect on basal current
(2.1 ± 7.3%, n= 6, t-test p= 0.542). These results suggest that the
intermediate conformation visited in the Apo state is associated
with a non-signaling state of the TMD.
An intermediate FRET state of ~0.3 has been observed
previously in mGluR2/2, but it was very short-lived and could
only be visualized as a low-incidence shoulder when large
numbers of transitions, acquired at a glutamate concentration
near the EC50, were aligned temporally13. We examined the
single-molecule activation-deactivation dynamics at near the
glutamate EC50 for mGluR2/7. We performed these experiments
with a more photo-stable donor/acceptor dye pair (LD555/
LD655, Förster radius 52 Å) and 10-times faster acquisition
(100 Hz). We found that, unlike mGluR2/2, which toggles back
and forth between the resting 0.45 and activated 0.20 FRET states,
with rarely resolved, brief occupancies at intermediate FRET
levels (Fig. 7a and Supplementary Fig. 6a), mGluR2/7 divides its
time between the ~0.45 FRET state, the ~0.20 FRET state and a
~0.30 intermediate FRET level, with short-lived occupancies of
the resting and activated conformations and substantial time
spent in the intermediate conformation (Fig. 7b and Supplemen-
tary Fig. 6b). The distinct activation/deactivation kinetics are
reﬂected in a more extended donor/acceptor cross-correlation in
mGluR2/7 (Fig. 7c).
Thus, along with enhanced afﬁnity and boosted single subunit
activation, the mGluR2/7 heterodimer displays a unique form of
spontaneous partial activation, in absence of agonist and with the
LBDs open, as well as altered conformational dynamics.
Discussion
The mGluR7/7 homodimer is known, based on effector activa-
tion, to have unusually low apparent afﬁnity for glutamate23. Our
measure of the glutamate-induced structural rearrangement of
the LBDs reveals an EC50 of 38 mM, ~4000-fold lower than that
of the other mGluRs. Along with this, we ﬁnd that maximal
activation by glutamate only reaches ~10%, as determined from
occupancy of the activated conformation, where the LBD clam-
shells are both closed and rotated, producing our measured low-
FRET state. Despite this large difference in relative occupancy, the
absolute smFRET levels of the resting and activated states in
mGluR7/7 are similar to those of mGluR2/2, mGluR3/3, and
mGluR2/313,31, suggesting that mGluR7/7 undergoes the same
activation rearrangements. We show that occupancy of the acti-
vated conformation is elevated by a mutation that increases
glutamate afﬁnity, or by presentation of the glutamate on a stiff
tethered linker that docks it into the binding pocket, or by a
group III selective synthetic agonist, indicating that the problem
with mGluR7/7 is not is ability to activate, but the ability of free
glutamate to stabilize the activated conformation.
The very low afﬁnity and low efﬁcacy of activation by gluta-
mate of mGluR7/7 poses a functional conundrum. Even within
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mGluR7 (m,GluR2/7) at a glutamate concentration near the EC50 (4 µM) imaged at 10× speed (100 Hz) with photobleaching resistant dyes (donor
BC-LD555 or BG-LD555 and acceptor BG-LD655). a, b mGluR2/2 and mGluR2/7 transition between resting (high FRET) and activated (low FRET),
but CLIP-mGluR2/SNAP-mGluR7 spends much of the time at an intermediate FRET level. c Donor/acceptor cross-correlation decays over longer
time in mGluR2/7. Both samples ﬁt with double exponential decay, mGluR2/2 R2= 0.9120 (8 movies, 396 molecules, s.e.m. error bars) and
mGluR2/7 R2= 0.9740 (8 movies, 384 molecules, s.e.m. error bars).
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the low volume synaptic cleft, and immediately after glutamate
release, glutamate is estimated to reach a peak of only 1–3 mM
peak and for less than one millisecond37,38. Spillover from nearby
synapses is thought to reach much lower concentrations56. Thus,
the afﬁnity and efﬁcacy of mGluR7/7 appear to be too low for
signiﬁcant activation under physiological conditions. And yet,
pharmacological and genetic knock-out studies suggest that
mGluR7 does function at synapses57–59. Also, the pharmacolo-
gical proﬁle differs from what is measured from mGluR7
expressed alone in non-neuronal cell lines, and that which is
measured in neuronal tissue60 suggesting a biochemical difference
between mGluR7 in neurons and in non-neuronal cells. We
considered that heterodimerization, which is known to occur
between mGluR7 and other group III mGluRs, as well as with
group II mGluRs, may yield a receptor that operates in the range
of physiological glutamate. We found that mGluR7 expression
overlaps with that of mGluR2 in the hippocampus, that mGluR7
and mGluR2 co-immune precipitate. Strikingly, the mGluR2/7
heterodimer has high afﬁnity and efﬁcacy. But heterodimerization
with mGluR2 does more than simply bring mGluR7 into the
physiological range, it activates more efﬁciently and at lower
agonist concentration than even mGluR2/2. This is associated
with a form of cooperativity, in which an unliganded mGluR2
greatly enhances activation by agonist bound to mGluR7, and vice
versa, and with a unique conformational pathway to activation, in
which mGluR2/7 partially activates in the Apo state, even when
its LBD is held open by antagonist.
mGluRs must dimerize to signal32,61,62, and, in the dimer, acti-
vation of only one subunit produces low efﬁcacy activation.
This was originally shown in mGluR5/5, where a wild-type
subunit was dimerized with one carrying the YADA binding site
mutant subunit, which drastically lowers afﬁnity46. The glutamate
concentration-response curve of mGluR5/mGluR5(YADA) is
biphasic: a ﬁrst low glutamate concentration component, where
only the wild-type subunit is expected to bind, yields ~20% of
maximal activation achieved at much higher glutamate concentra-
tion, which is expected to also bind the YADA subunit. Similar
behavior has been described for mGluR2/mGluR2(YADA)13
and we conﬁrm that here. We ﬁnd that maximal activation of
mGluR2/mGluR2(YADA)—at high glutamate (where both the high
afﬁnity wild-type and low afﬁnity YADA subunits are both
expected to be glutamate bound—only yields ~30% occupancy of
the low FRET activated conformation, in contrast to the full
occupancy seen in the wild-type mGluR2/2 dimer.
mGluR2/7 is expected to function similarly to mGluR2/
mGluR2(YADA), with the naturally very low afﬁnity wild-type
mGluR7 subunit taking the place of the mutant mGluR2(YADA)
subunit. However, mGluR2/7 breaks expectation in two ways.
First, compared to mGluR2/2, the mGluR2/7 heterodimer acti-
vates at lower glutamate concentrations. Second, in contrast to
mGluR2/mGluR2(YADA), mGluR2/7 has ~4-fold higher efﬁcacy
at 1 mM glutamate, the top of the ﬁrst component of the biphasic
concentration-response relation, when only the wild-type
mGluR2 subunit is expected to be liganded (~80% of maximal
activation) and achieves full occupancy of the low FRET activated
conformation at the top of the biphasic concentration-response
relation, ~3-fold better than the maximal activation of mGluR2/
mGluR2(YADA).
Compared to mGluR7/7, the mGluR2/7 heterodimer is activated
with higher efﬁcacy by both the group III selective agonist LSP4-
2022 and by the tethered glutamate photoswitch D-MAG-0, even
though in mGluR7/7 both subunits are bound by agonist, whereas
in the mGluR2/7 heterodimer only the mGluR7 subunit has the
agonist and the mGluR2 subunit is in the Apo state. This suggests
that agonist-induced closure of the mGluR7 LBD drives the empty
mGluR2 LBD to also close and rotate. This cooperative effect works
in the opposite direction also: The presence of the mGluR2 subunit
enhances agonist binding by the mGluR7 subunit. This is seen with
the competitive antagonist 100 μM LY341495, which appears to
completely displace D-MAG-0 from the binding site in the
mGluR7/7 homodimer (shifting completely to the resting high
FRET state), whereas in the mGluR2/7 heterodimer 100 μM
LY341495 has almost no effect, suggesting that D-MAG-0 has a
much higher afﬁnity for mGluR7 when it is paired in the hetero-
dimer with mGluR2. Thus, mGluR2/7 has a unique form of het-
eromeric cooperativity in which each subunit in its Apo state acts as
a positive allosteric modulator of its partner subunit.
While some GPCRs, such as rhodopsin, have very low basal
activation, others activate in absence of agonist63. Basal activation
in absence of glutamate occurs in some mGluRs, including in
mGluR3/3 and mGluR2/3, which are partially activated by cal-
cium binding near the mGluR3 orthosteric site13,64,65. We see
fundamental differences between basal activation of mGluR2/7
and examples described previously. mGluR3/3 and mGluR2/3
basal activation appears as FRET transitions from ~0.45 FRET to
~0.2 FRET and this transition is mediated by LBD closure and
can be blocked by orthosteric antagonist LY341495 which stabi-
lizes the open conformation of the LBD. However, the basal
activity in mGluR2/7 is characterized by transitions between
~0.45 FRET and intermediate ~0.3 FRET and is not affected by
LY341495, but is blocked by NAMs, which stabilize the inactive
conformation of the TMD.
Activation is thought to proceed from the resting state (R) to
the active state (A), starting with closure of the LBDs on the
agonist (Roo→ Rcc), followed by LBD rotation (Rcc→ Rcc*),
and by stabilization of a rearranged state of the TMD that
includes a whole-TMD rotation and a tilt of TM6 to open the G-
protein binding pocket: Rcc*→Acc* (Fig. 8a)29,66. Since spon-
taneous entry into the intermediate state occurs with the LBDs
held open by LY341495 in zero glutamate (so that LBD closure
does not contribute to the reduced FRET), and NAMs prevent
entry into this state, we propose that the intermediate FRET state
reﬂects a partially activated conformation in which the LBD is
open but rotated. Our functional analysis indicates that this
partially activated conformation is signaling inactive (Roo*)
(Fig. 8a). This unusual activation pathway in mGluR2/7 is asso-
ciated with a unique potency of single subunit liganding, which
achieves ~80% of maximal activation as compared to only ~20%
seen in mGluR2/mGluR2(YADA) (Fig. 8b).
Near the EC50 glutamate concentration, where the receptor
spends roughly equal time in the resting and activated states,
mGluR2/2
mGluR2/7
Bound 2/2 2/7
1
2
0.2
1.0
0.8
1.0
(active state 
fraction)
= rotated
*
a b
Fig. 8 State diagram model of activation pathway. a The transition of an
mGluR from the resting state (Roo) to the active state (Acc) involves
transition of the two LBDs from the open state (o) to the closed state
(o), and rotation (*) of the LBDs relative to one another. In absence of
agonist, mGluR2/2 is stable in Roo, and previous work has shown that
the main route of activation is Roo→ Roc→ Rcc→ Rcc*, although a small
amount of activation is possible from Roc. In contrast, we ﬁnd that
mGluR2/7 spontaneously enters a partially activated (functionally
inactive) conformation when both LBDs are held open by antagonist,
which we propose as Roo→ Roo*. b The energetic difference results in
much higher occupancy of the fully active state in mGluR2/7 in which
only one subunit is liganded by agonist.
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mGluR2/7 is more dynamic than mGluR2/2 and spends sub-
stantial time in the partially activated state. Thus, the enhanced
afﬁnity and efﬁcacy of mGluR2/7 are associated with a favored
transition to a partially activated state where the LBD is rotated
but the TMD is in the non-signaling state. Recent work has
provided the ﬁrst structure of a full length, dimeric mGluR
complex in the resting and active conformations29 that are
compatible with earlier evidence for TMD rotation66. Our
observations indicate that the conformational pathway between
these states has several possible paths.
In conclusion, our study reveals a specialized heteromeric
cooperativity in mGluRs in which an unliganded subunit confers
on its dimer partner both enhanced glutamate afﬁnity and the
ability of the single subunit bound state to fully activate the
receptor. This cooperativity is associated with a conformational
pathway to activation that is not seen in other mGluRs. Instead of
the canonical pathway of sequential LBD closure on agonist fol-
lowed by LBD rotation, it appears that the LBD rotates even when
it is open, leading to a partially activated state even when both
members of the dimer are in the Apo state. Unusually too, while
threshold sensitivity is enhanced, the concentration-response
relation of the mGluR2/7 heteromer is shallower overall and
saturates at higher concentration, adding to the ability to respond
to low concentration spillover from a distance, a wider dynamic
range to respond proportionately to particularly high glutamate
from nearby sources.
Methods
Drugs. LSP4-2022 was obtained according to the general procedure following
Fig. 967, with improvements to minimize the formation and discard L-AP4, a side
product with selective and potent group III mGluR agonist activity: (i) The use of
degassed solvent during the formation of the second C-P bond dramatically
reduces the presence of the corresponding phosphonate; (ii) The puriﬁcation of the
crude LSP4-2022 by C-18 chromatography using a slow gradient (H2O+ 0.1%
HCO2H/MeCN+ 0.1% HCO2H: from 100/0 to 90/10), instead of successive
cation- and anion- exchange resins, saves time and increases the overall yield of the
ﬁnal compound.
Cell culture and transfection. HEK293T cells were cultured in DMEM with 5%
FBS on poly-L- lysine-coated glass coverslips. HEK293T cells were obtained from
the UC Berkeley MCB tissue culture facility, authenticated by DDC Medical, and
tested negative for mycoplasma contamination. Previously described HA–SNAP
and Flag–CLIP-tagged rat mGluR cDNA were generously provided by J. P. Pin.
DNA plasmids were transfected into cells using lipofectamine 2000 (Thermo
Fisher). For electrophysiology experiments, cells were transfected with wild-type-
mGluR2 or wild-type- mGluR7 or SNAP-mGluR2(F756D), GIRK1-F137S, and
yellow ﬂuorescent protein (YFP) (as a transfection marker) at a 7:7:1 ratio with
0.7 mg plasmid per well for receptor and channel. For FRET experiments, cells
were transfected with SNAP and CLIP-tagged constructs at a ratio of 1:2 with
0.3 mg of SNAP–mGluR DNA per well.
Patch clamp electrophysiology. Whole-cell patch clamp recordings from single
isolated cells were performed 24–48 h after transfection, in a high potassium extra-
cellular solution containing (in mM): 120 KCl, 29 NaCl, 1 MgCl2, 2 CaCl2 and 10
HEPES, pH 7.4. Cells were voltage clamped to −60 mV using an Axopatch 200B
ampliﬁer (Axon Instruments) and membrane currents were recorded. Glass pip-
ettes of resistance between 3 and 8MΩ were ﬁlled with intracellular solution
containing (in mM): 140 KCl, 10 HEPES, 3 Na2ATP, 0.2 Na2GTP, 5 EGTA and
3 MgCl2, pH 7.4. Data were acquired with a 2 kHz acquisition rate and low-pass
ﬁltered with a 4-pole Bessel ﬁlter at 1 kHz. Data acquisition and analysis were
performed using pCLAMP 10 software (Axon Instruments).
Photoswitching. Illumination was applied to the entire ﬁeld of view using either a
Polychrome V monochromator (TILL Photonics) through a 20× objective, or a
Lambda DG4 high-speed wavelength switcher (Sutter Instruments) with 380 nm
and 500 nm ﬁlters through a 40× objective. pClamp software was used for both
data acquisition and control of illumination. BGAG labeling was done by applying
1.5 μM BGAG for 45 min at 37 °C. To conjugate D-MAG-0, cells were incubated in
50–100 µM D-MAG-0for 30–60 min in the dark at 23–27 °C in standard extra-
cellular cell buffer.
FRET pair ﬂuorescent dye labeling of protein-tagged mGluRs. Approximately
24–48 h after transfection, cells were labeled while attached to poly-L-lysine-coated
coverslips. Culture media was removed and coverslips were washed and transferred
to extracellular solution containing (in mM): 135 NaCl, 5.4 KCl, 2 CaCl2, 1 MgCl2,
10 HEPES, pH 7.4. Cells were labeled at 37 °C with one or two SNAP-reactive
(benzylguanine, BG) dyes at 1.5 μM for 45 min, and then, if a CLIP-tagged mGluR
was used, they were washed and labeled with a CLIP-reactive (benzylcytosine, BC)
dye at 3 μM for 45 min. For most of the experiments (Figs. 1–6 and Supplemental
Figs. 1–5, except Supplemental Fig. 1c) DY-547 (NEB) was used as a donor and
Alexa-647 (NEB) as an acceptor (in Supplemental Fig. 1c Atto-488 was the donor
and Atto-594 was the acceptor; Company). In Fig. 7 and Supplemental Fig. 6, LD-
655 was the donor and LD-655 was the acceptor (Lumidyne). The ﬂuorophores
were diluted in extracellular solution and coverslips were washed in between
labeling with donor and acceptor.
Ensemble FRET. After labeling, cells were mounted on an upright, scanning
confocal microscope (Zeiss LSM 780) and imaged with a 20X objective. Donor
excitation was performed using a 561-nm laser and images were taken in the donor
and acceptor channels at 1 Hz. Clusters of cells were analyzed together and FRET
was calculated as FRET= (IA)/(ID+ IA), in which ID is the ﬂuorescence donor
intensity and IA is the ﬂuorescence acceptor intensity. For individual traces, FRET
was normalized to the basal FRET value observed before application of drugs.
FRET changes calculated for dose–response curves were normalized to the
response to saturating glutamate (10 mM) and dose–response curves were obtained
from multiple cell clusters and averaged from at least three experiments. Fitting of
dose–response curves was performed using Prism (Graphpad). All drugs, except
LSP4-2022, which we synthesized, were purchased from Tocris. Drugs were
delivered with a gravity-driven perfusion system.
smPull receptor isolation and surface display. To inhibit nonspeciﬁc protein
adsorption, ﬂow cells for single-molecule experiments were prepared as previously
described13 using mPEG (Laysan Bio) passivated glass coverslips (VWR) and
doped with biotin PEG16. Before each experiment, coverslips were incubated with
NeutrAvidin (Thermo), followed by 10 nM biotinylated secondary antibody
(donkey anti-rabbit, Jackson ImmunoResearch). For receptor immunopuriﬁcation,
10 nM anti-mGluR2 primary antibody (abcam, ab150387) or 10 nM anti-mGluR7
antibody (abcam, ab53705), or 15 nM anti-HA antibody (abcam, ab26228) was
incubated in the chamber (Fig. 1e). Between each conjugation step, the chambers
were ﬂushed to remove free reagents. The antibody dilutions and washes were done
in T50 buffer (50 mM NaCl, 10 mM Tris, pH 7.5). For single-molecule experi-
ments, fresh cells expressing tagged mGluR constructs were labeled, as described
above, and recovered from coverslips by incubating with Ca2+ free PBS buffer for
5–10 min followed by gentle pipetting. Cells were then pelleted by spinning at
5,000 g for 5 min and lysed in lysis buffer consisting of 150 mM NaCl, 1 mM
EDTA, protease inhibitor cocktail (Thermo Scientiﬁc) and 1.2% IGEPAL (Sigma).
After 1 h incubation at 4 C°, lysate was centrifuged at 16,000 × g for 20 min. and the
supernatant was collected and kept on ice. To achieve sparse immobilization of
labeled receptors on the surface, the cell lysate was diluted (ranging from 5× to 50×
dilution depending on the expression and labeling efﬁciency) and applied to
coverslips. After achieving optimum surface immobilization (~400 molecules in a
2000 μm2 imaging area), unbound receptors were washed out of the ﬂow chamber
and the ﬂow cells were then washed extensively (up to 50× the cell volume).
smFRET measurements. Receptors were imaged for smFRET in imaging buffer
consisting of (in mM) 3 Trolox, 120 KCl, 29 NaCl, 2 CaCl2, 1 MgCl2, 50 HEPES,
0.04% IGEPAL and an oxygen scavenging system (0.8% dextrose, 0.8 mgml−1
glucose oxidase, and 0.02 mgml−1 catalase), pH 7.4. Reagents were purchased from
Sigma and were all UltraPure grade (purity > 99.99%). All buffers were made in
Fig. 9 Improved synthesis of LSP4-2022a. aReagents and conditions: (i) 4-(Carboxymethoxy)benzaldehyde, BSA, degassed CH2Cl2, RT, 16 h; (ii) a 6M aqueous
HCl, reﬂux, 5 h; b C-18 ﬂash chromatography. Abbreviations: BSA: N,O-bis(trimethylsilyl)acetamide; Cbz: benzyloxycarbonyl; L-AP4: L-2-amino-4-
phosphonobutyric acid; Me: methyl; RT: room temperature.
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UltraPure distilled water (Invitrogen). For the experiments done in the absence of
Ca2+, 10 mM EGTA and 1mM EDTA were added to the imaging buffer. Catalase
was diluted in T50 buffer and passed through a spin column 3× (BioRad).
Samples were imaged with a 1.65 na ×60 objective (Olympus) on a TIRF
microscope with 100 ms time resolution unless stated otherwise. Lasers at 532 nm
(Cobolt) and 632 nm (Melles Griot) were used for donor and acceptor excitation,
respectively. FRET efﬁciency was calculated as (IA− 0.1ID)/(ID+ IA), in which ID
and IA are the donor and acceptor intensity, respectively, after back-ground
subtraction. Imaging was with 100 ms acquisition time (10 Hz) with an Andor iXon
897 EMCCD camera (Figs. 1–6 and Supplemental Figs. 1–5) or with 10 ms
acquisition time (100 Hz) with a Photometrics Prime 95B cMOS camera (Fig. 7 and
Supplemental Fig. 6) using Lumidyne LD555 as donor and Lumidyne LD655 as
acceptor (Förster radius ~52 Å). Dyes were conjugated to benzyguanine and
benzylecytosine to allow for labeling of SNAP and CLIP proteins, respectively.
smFRET data analysis. Single-molecule intensity traces showing single-donor and
single-acceptor photobleaching with a stable total intensity for longer than 5 s were
collected (20–30% of total molecules per imaging area). Individual traces were
smoothed using a nonlinear ﬁlter68 with following ﬁlter parameters: window= 2,
M= 2 and P= 15. Each experiment was performed >4 times to ensure reprodu-
cibility. smFRET histograms were compiled from >100 molecules per condition.
(100 ms time resolution). Error bars in the histograms represent the standard error
from >4 independent movies. To ensure that traces of different lengths contribute
equally, histograms from individual traces were normalized to one before com-
piling. Gaussian ﬁtting to histograms was done in Origin Pro. smFRET histograms
were ﬁt to two Gaussians, centered on high (~0.45) and low (~0.2) FRET levels for
mGluR2/2 and mGluR2/7 and a single Gaussian for mGluR2/7 (center ranging
from 0.2 to 0.45). For dose–response relations, the area underneath the low FRET
Gaussian was used as a measure of active state occupancy.
Immunostaining for brain sections. Mice were anaesthetized and perfused
transcardially with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH
7.4). The brains were removed, postﬁxed overnight at 4 °C and sectioned at a
thickness of 50 μm. Free-ﬂoating sections were incubated in blocking solution (PBS
containing 10% normal sheep serum and 0.1% Triton X-100) overnight, followed
by incubation with primary antibodies(diuluted 1 to 500) for 3 days and, after
extensive washing, with Alexa 488- or Alexa 647-conjugated secondary antibodies
(Molecular Probes) overnight at 4 °C.
Western blot analysis. Cells were scraped into lysis buffer (50mM Tris- HCl, pH
7.5, and 150mM NaCl) containing 0.5% IGEPAL and protease inhibitor mixture
(Roche) and incubated on ice for 20–30min. The supernatant was separated from
cell debris by centrifugation at 16,000 × g for 10min at 4 °C. Aliquots of lysate were
heated in SDS sample buffer (containing 10% SDS and 9.3% DTT) at 95 °C for 5min.
Samples were loaded on SDS–PAGE and transferred to nitrocellulose membranes
(Bio-Rad). After transfer, membranes were blocked in TBST (25mM Tris, 150mM
NaCl, and 0.05% Tween 20) containing 5% nonfat milk at room temperature for 1 h.
mGluR2 antibodies, mGluR7 and mGluR3 (Novus Biologicals, cat. # NBP2-61843)
antibodies were diluted in blocking solution and incubated with the membranes at
4 °C overnight. Membranes were then washed with TBST and incubated with HRP-
conjugated goat anti-rabbit IgG secondary antibody (Santa Cruz Biotechnology,
catalog #sc-2004, 1:7500 diluted in blocking buffer or Jackson ImmunoResearch
Laboratories, catalog #111-035-144, 1:10,000 diluted in blocking buffer).
Co-immunoprecipitation from brain tissue. Brain samples were collected from
Spraque Dawely rats, suspended in lysis buffer (50 mM Tris- HCl, pH 7.5, and 150
mM NaCl) containing protease inhibitor mixture (Roche). Tissue samples were
homogenized and sonicated. Cell membrane fractions were separated by cen-
trifugation at 100,000 × g and cell pellet was resuspended in lysis buffer containing
1.5% IGEPAL and protease inhibitor mixture (Roche). Cell were rocked at 4 °C for
one hour then supernatant was cleared by centrifugation at 16,000 × g for 20 min at
4 °C. Supernatant precleared with Pierce Protein A/G magnetic beads (Thermo-
Fisher) followed by incubation with primary antibody conjugated protein A/G
magnetic beads overnight at 4 °C. Beads were washed and protein was eluted in
SDS sample buffer (containing 10% SDS and 9.3% DTT) at 95 °C for 5 min.
Samples were run on western blot as described above.
Data availability
Data supporting the ﬁndings of this manuscript are available from the corresponding
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